U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06892093) titled 'Probiotics for Prevention of Pyrotinib/Neratinib-Induced Diarrhea in Breast Cancer Patients' on March 11.
Brief Summary: This study aims to evaluate the efficacy and safety of probiotics for the prevention of diarrhea in patients with breast cancer receiving tyrosine kinase inhibitors (TKIs), specifically Pyrotinib or Neratinib.
Study Design: This is a prospective, randomized controlled clinical trial. Participants will be randomly assigned to either a probiotics intervention group or a placebo-controlled group. Both groups will be permitted to use loperamide as needed for diarrhea management.
Primary Objective: To evaluate the e...